Pyruvate kinase M2: Regulatory circuits and potential for therapeutic intervention

Current Pharmaceutical Design

Volumn 20, Issue 15, 2014, Pages 2595-2606

  Gupta, Vibhor ^a,b   Wellen, Kathryn E ^b   Mazurek, Sybille ^c   Bamezai, Rameshwar N K ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Alternative splicing; Cancer metabolism; Cancer therapeutics; Glycolysis; Network; PKM2 regulation; Post translational modification; Pyruvate kinase M2 (PKM2)

Indexed keywords

MICRORNA; PYRUVATE KINASE; PYRUVATE KINASE M2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; CANCER DIAGNOSIS; CANCER THERAPY; CELL PROLIFERATION; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME REGULATION; GENE EXPRESSION; GENE MUTATION; GLYCOLYSIS; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYME ACTIVATION; GENETICS; METABOLISM; NEOPLASMS; PHYSIOLOGY;

ANIMALS; ENZYME ACTIVATION; GLYCOLYSIS; HUMANS; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRUVATE KINASE;

EID: 84903721134     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990484     Document Type: Article

References (110)

1. Dombrauckas JD, Santarsiero BD, Mesecar AD. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 2005; 44: 9417-29.
2. Steinberg P, Klingelhoffer A, Schafer A, et al. Expression of pyruvate kinase M2 in preneoplastic hepatic foci of Nnitrosomorpholine-treated rats. Virchows Arch 1999; 434: 213-20.
3. Brinck U, Eigenbrodt E, Oehmke M, Mazurek S, Fischer G. L-and M2-pyruvate kinase expression in renal cell carcinomas and their metastases. Virchows Arch 1994; 424: 177-85.
4. Rodriguez-Horche P, Luque J, Perez-Artes E, Pineda M, Pinilla M. Comparative kinetic behaviour and regulation by fructose-1,6-bisphosphate and ATP of pyruvate kinase from erythrocytes, reticulocytes and bone marrow cells. Comp Biochem Physiol B 1987; 87: 553-7.
5. Yamada K, Noguchi T. Regulation of pyruvate kinase M gene expression. Biochem Biophys Res Commun 1999; 256: 257-62.
6. Reinacher M, Eigenbrodt E, Schering B, Schoner W. Immunohistochemical localization of pyruvate kinase isoenzymes in chicken tissues. Histochemistry 1979; 64: 145-61.
7. Reinacher M, Eigenbrodt E. Immunohistological demonstration of the same type of pyruvate kinase isoenzyme (M2-Pk) in tumors of chicken and rat. Virchows Arch B Cell Pathol Incl Mol Pathol 1981; 37: 79-88.
8. Yamada K, Noguchi T. Nutrient and hormonal regulation of pyruvate kinase gene expression. Biochem J 1999; 337 (Pt 1): 1-11.
9. Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit Rev Oncog 1992; 3: 91-115.
10. Bluemlein K, Gruning NM, Feichtinger RG, Lehrach H, Kofler B, Ralser M. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2010; 2: 393-400.
11. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005; 15: 300-8.
12. Tani K, Fujii H, Tsutsumi H, et al. Human liver type pyruvate kinase: cDNA cloning and chromosomal assignment. Biochem Biophys Res Commun 1987; 143: 431-8.
13. Satoh H, Tani K, Yoshida MC, Sasaki M, Miwa S, Fujii H. The human liver-type pyruvate kinase (PKL) gene is on chromosome 1 at band q21. Cytogenet Cell Genet 1988; 47: 132-3.
14. Lenzner C, Nurnberg P, Jacobasch G, Gerth C, Thiele BJ. Molecular analysis of 29 pyruvate kinase-deficient patients from central Europe with hereditary hemolytic anemia. Blood 1997; 89: 1793-9.
15. Kanno H, Fujii H, Wei DC, et al. Frame shift mutation, exon skipping, and a two-codon deletion caused by splice site mutations account for pyruvate kinase deficiency. Blood 1997; 89: 4213-8.
16. van Wijk R, Huizinga EG, van Wesel AC, van Oirschot BA, Hadders MA, van Solinge WW. Fifteen novel mutations in PKLR associated with pyruvate kinase (PK) deficiency: structural implications of amino acid substitutions in PK. Hum Mutat 2009; 30: 446-53.
17. Pissard S, Max-Audit I, Skopinski L, et al. Pyruvate kinase deficiency in France: a 3-year study reveals 27 new mutations. Br J Haematol 2006; 133: 683-9.
18. University, Medical, Centre, Utrecht. (Home page online). http://www.pklrmutationdatabase.com/
19. Wang C, Chiarelli LR, Bianchi P, et al. Human erythrocyte pyruvate kinase: characterization of the recombinant enzyme and a mutant form (R510Q) causing nonspherocytic hemolytic anemia. Blood 2001; 98: 3113-20.
20. Valentini G, Chiarelli LR, Fortin R, et al. Structure and function of human erythrocyte pyruvate kinase. Molecular basis of nonspherocytic hemolytic anemia. J Biol Chem 2002; 277: 23807-14.
21. Wijk R, van Wesel AC, Thomas AA, Rijksen G, van Solinge WW. Ex vivo analysis of aberrant splicing induced by two donor site mutations in PKLR of a patient with severe pyruvate kinase deficiency. Br J Haematol 2004; 125: 253-63.
22. Anitha M, Kaur G, Baquer NZ, Bamezai R. Dominant negative effect of novel mutations in pyruvate kinase-M2. DNA Cell Biol 2004; 23: 442-9.
23. Akhtar K, Gupta V, Koul A, Alam N, Bhat R, Bamezai RN. Differential behavior of missense mutations in the intersubunit contact domain of the human pyruvate kinase M2 isozyme. J Biol Chem 2009; 284: 11971-81.
24. Ikeda Y, Tanaka T, Noguchi T. Conversion of non-allosteric pyruvate kinase isozyme into an allosteric enzyme by a single amino acid substitution. J Biol Chem 1997; 272: 20495-501.
25. Webb BA, Chimenti M, Jacobson MP, Barber DL. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer 2011; 11: 671-7.
26. Gupta V, Kalaiarasan P, Faheem M, Singh N, Iqbal MA, Bamezai RN. Dominant negative mutations affect oligomerization of human pyruvate kinase M2 isozyme and promote cellular growth and polyploidy. J Biol Chem 2010; 285: 16864-73.
27. Friesen RH, Lee JC. The negative dominant effects of T340M mutation on mammalian pyruvate kinase. J Biol Chem 1998; 273: 14772-9.
28. Susan-Resiga D, Nowak T. Monitoring active site alterations upon mutation of yeast pyruvate kinase using 205Tl+ NMR. J Biol Chem 2003; 278: 40943-52.
29. Hitosugi T, Kang S, Vander Heiden MG, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal 2009; 2: ra73.
30. Noguchi T, Yamada K, Inoue H, Matsuda T, Tanaka T. The L-and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters. J Biol Chem 1987; 262: 14366-71.
31. Noguchi T, Inoue H, Tanaka T. The M1-and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J Biol Chem 1986; 261: 13807-12.
32. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010; 463: 364-8.
33. Wang Z, Chatterjee D, Jeon HY, et al. Exon-centric regulation of pyruvate kinase M alternative splicing via mutually exclusive exons. J Mol Cell Biol 2011, in press.
34. Schafer D, Hamm-Kunzelmann B, Hermfisse U, Brand K. Differences in DNA-binding efficiency of Sp1 to aldolase and pyruvate kinase promoter correlate with altered redox states in resting and proliferating rat thymocytes. FEBS Lett 1996; 391: 35-8.
35. Schafer D, Hamm-Kunzelmann B, Brand K. Glucose regulates the promoter activity of aldolase A and pyruvate kinase M2 via dephosphorylation of Sp1. FEBS Lett 1997; 417: 325-8.
36. Netzker R, Weigert C, Brand K. Role of the stimulatory proteins Sp1 and Sp3 in the regulation of transcription of the rat pyruvate kinase M gene. Eur J Biochem 1997; 245: 174-81.
37. Discher DJ, Bishopric NH, Wu X, Peterson CA, Webster KA. Hypoxia regulates beta-enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element. J Biol Chem 1998; 273: 26087-93.
38. Sun Q, Chen X, Ma J, et al. Mammalian target of rapamycin upregulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A 2011; 108: 4129-34.
39. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-14.
40. Pillai RS. MicroRNA function: multiple mechanisms for a tiny RNA? RNA 2005; 11: 1753-61.
41. Kefas B, Comeau L, Erdle N, Montgomery E, Amos S, Purow B. Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro Oncol 2010; 12: 1102-12.
42. Wong TS, Liu XB, Chung-Wai Ho A, et al. Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int J Cancer 2008; 123: 251-7.
43. Traweger A, Lehner C, Farkas A, et al. Nuclear Zonula occludens-2 alters gene expression and junctional stability in epithelial and endothelial cells. Differentiation 2008; 76: 99-106.
44. Zwerschke W, Mazurek S, Massimi P, Banks L, Eigenbrodt E, Jansen-Durr P. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc Natl Acad Sci U S A 1999; 96: 1291-6.
45. Ashizawa K, Willingham MC, Liang CM, Cheng SY. In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1,6-bisphosphate. J Biol Chem 1991; 266: 16842-6.
46. Kato H, Fukuda T, Parkison C, McPhie P, Cheng SY. Cytosolic thyroid hormone-binding protein is a monomer of pyruvate kinase. Proc Natl Acad Sci U S A 1989; 86: 7861-5.
47. Diaz-Jullien C, Moreira D, Sarandeses CS, Covelo G, Barbeito P, Freire M. The M2-type isoenzyme of pyruvate kinase phosphory lates prothymosin alpha in proliferating lymphocytes. Biochim Biophys Acta 2010; 1814: 355-65.
48. Mazurek S. Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst Schering Found Symp Proc 2007: 99-124.
49. Eigenbrodt E, Glossmann H. Glycolysis-one of the keys to cancer? Trends Pharmacol. Sci. 1980; 1: 240-245.
50. Mazurek S. Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 2011; 43: 969-980.
51. Mazurek S, Drexler HC, Troppmair J, Eigenbrodt E, Rapp UR. Regulation of pyruvate kinase type M2 by A-Raf: a possible glycolytic stop or go mechanism. Anticancer Res 2007; 27: 3963-71.
52. Marchut E, Guminska M, Kedryna T. The inhibitory effect of various fatty acids on aerobic glycolysis in Ehrlich ascites tumour cells. Acta Biochim Pol 1986; 33: 7-16.
53. Presek P, Reinacher M, Eigenbrodt E. Pyruvate kinase type M2 is phosphorylated at tyrosine residues in cells transformed by Rous sarcoma virus. FEBS Lett 1988; 242: 194-8.
54. Eigenbrodt E, Mazurek S, Friis RR. Eigenbrodt E, Mazurek S, FriisRR. Double role of pyruvate kinase type M2 in the regulation of phosphometabolite pools. In: Cell Growth and Oncogenesis (P. Bannasch, D. Kanduc, S. Papa and J.M. Tager, eds.) Birkhäuser Verlag Basel/Switzerland. 1998: 15-30.
55. Siwko S, Mochly-Rosen D. Use of a novel method to find substrates of protein kinase C delta identifies M2 pyruvate kinase. Int J Biochem Cell Biol 2007; 39: 978-87.
56. Lv L, Li D, Zhao D, et al. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell 2011; 42: 719-30.
57. Wellen KE, Thompson CB. Cellular metabolic stress: considering how cells respond to nutrient excess. Mol Cell 2010; 40: 323-32.
58. Luo W, Hu H, Chang R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011; 145: 732-44.
59. Anastasiou D, Poulogiannis G, Asara JM, et al. Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Antioxidant Responses. Science 2011.
60. Gupta V, Bamezai RN. Human pyruvate kinase-M2: "A multifunctional protein". Protein Sci 2010; 19: 2031-44.
61. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008; 452: 181-6.
62. Mazurek S, Zwerschke W, Jansen-Durr P, Eigenbrodt E. Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex. Biochem J 2001; 356: 247-56.
63. Mazurek S, Zwerschke W, Jansen-Durr P, Eigenbrodt E. Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7. Oncogene 2001; 20: 6891-8.
64. Shimada N, Shinagawa T, Ishii S. Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein. Genes Cells 2008; 13: 245-54.
65. Hoshino A, Hirst JA, Fujii H. Regulation of cell proliferation by interleukin-3-induced nuclear translocation of pyruvate kinase. J Biol Chem 2007; 282: 17706-11.
66. Stetak A, Veress R, Ovadi J, Csermely P, Keri G, Ullrich A. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res 2007; 67: 1602-8.
67. Spoden GA, Morandell D, Ehehalt D, et al. The SUMO-E3 ligase PIAS3 targets pyruvate kinase M2. J Cell Biochem 2009; 107: 293-302.
68. Lee J, Kim HK, Han YM, Kim J. Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int J Biochem Cell Biol 2008; 40: 1043-54.
69. Luo W, Semenza GL. Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget 2011; 2: 551-6.
70. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007; 129: 465-72.
71. Ignacak J, Stachurska MB. The dual activity of pyruvate kinase type M2 from chromatin extracts of neoplastic cells. Comp Biochem Physiol B Biochem Mol Biol 2003; 134: 425-33.
72. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009; 324: 1076-80.
73. Yalcin A, Clem BF, Simmons A, et al. Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases. J Biol Chem 2009; 284: 24223-32.
74. Yang W, Xia Y, Ji H, et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 2011; 480: 118-22.
75. Eigenbrodt E, Gerbracht U, Mazurek S, Presek P, Friis RR. Carbohydrate metabolism and neoplasia: New perspectives for diagnosis and therapy. Biochemical and Molecular Aspects of Selected Cancers (T.G. Pretlow, T.P. Pretlow, eds.) Academic Press, Inc 1994; 2: 311-85.
76. Vander Heiden MG, Locasale JW, Swanson KD, et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 2011; 329: 1492-9.
77. Muellner S, Stark H, Niskanen P, Eigenbrodt E, Mazurek S, Fasold H. From target to lead synthesis In: Proteomics in Drug Research. Wiley-VCH, Weinheim 2006; 28 187-207.
78. Baumann P, Mandl-Weber S, Volkl A, et al. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther 2009; 8: 366-75.
79. Shawver LK, Schwartz DP, Mann E, et al. Inhibition of plateletderived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin Cancer Res 1997; 3: 1167-77.
80. Vander Heiden MG, Christofk HR, Schuman E, et al. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol 2009; 79: 1118-24.
81. Chen J, Xie J, Jiang Z, Wang B, Wang Y, Hu X. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene 2011; 42: 4297-4306.
82. Shi HS, Li D, Zhang J, et al. Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci 2010; 101: 1447-53.
83. Guo W, Zhang Y, Chen T, et al. Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J Cancer Res Clin Oncol 2011; 1: 65-72.
84. Li SL, Ye F, Cai WJ, et al. Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line. J Cell Biochem 2010; 109: 625-33.
85. Yoo BC, Ku JL, Hong SH, et al. Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines. Int J Cancer 2004; 108: 532-9.
86. Martinez-Balibrea E, Plasencia C, Gines A, et al. A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines. Mol Cancer Ther 2009; 8: 771-8.
87. Shin YK, Yoo BC, Hong YS, et al. Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance. Electrophoresis 2009; 30: 2182-92.
88. Jiang JK, Boxer MB, Vander Heiden MG, et al. Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg Med Chem Lett 2010; 20: 3387-93.
89. Boxer MB, Jiang JK, Vander Heiden MG, et al. Evaluation of substituted N, N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. J Med Chem 2010; 53: 1048-55.
90. Walsh MJ, Brimacombe KR, Veith H, et al. 2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg Med Chem Lett 2011; 21: 6322-7.
91. Spoden GA, Mazurek S, Morandell D, et al. Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation. Int J Cancer 2008; 123: 312-21.
92. Spoden GA, Rostek U, Lechner S, Mitterberger M, Mazurek S, Zwerschke W. Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply. Exp Cell Res 2009; 315: 2765-74.
93. Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ, Capaldi RA. Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res 2004; 64: 985-93.
94. Reitzer LJ, Wice BM, Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 1979; 254: 2669-76.
95. Cheng T, Sudderth J, Yang C, et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci U S A 2011; 108: 8674-9.
96. Guminska M, Stachurska MB, Ignacak J. Pyruvate kinase isoenzymes in chromatin extracts of Ehrlich ascites tumour, Morris hepatoma 7777 and normal mouse and rat livers. Biochim Biophys Acta 1988; 966: 207-13.
97. Thallion, Pharmaceutical, Inc. (Home page online). (http://www.thallion.com/en/drug-development/tln-232.php)
98. Duan HF, Hu XW, Chen JL, et al. Antitumor activities of TEM8-Fc: an engineered antibody-like molecule targeting tumor endothelial marker 8. J Natl Cancer Inst 2007; 99: 1551-5.
99. Ahmed AS, Dew T, Lawton FG, et al. M2-PK as a novel marker in ovarian cancer. A prospective cohort study. Eur J Gynaecol Oncol 2007; 28: 83-8.
100. Kaura B, Bagga R, Patel FD. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma. J Obstet Gynaecol Res 2004; 30: 193-6.
101. Kumar Y, Tapuria N, Kirmani N, Davidson BR. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker. Eur J Gastroenterol Hepatol 2007; 19: 265-76.
102. Luftner D, Mesterharm J, Akrivakis C, et al. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 2000; 20: 5077-82.
103. Ugurel S, Bell N, Sucker A, Zimpfer A, Rittgen W, Schadendorf D. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma. Int J Cancer 2005; 117: 825-30.
104. Wechsel HW, Petri E, Bichler KH, Feil G. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res 1999; 19: 2583-90.
105. Schneider J, Neu K, Grimm H, Velcovsky HG, Weisse G, Eigenbrodt E. Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res 2002; 22: 311-8.
106. Hardt PD, Mazurek S, Toepler M, et al. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 2004; 91: 980-4.
107. Zhang P, Gao WY, Turner S, Ducatman BS. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer 2003; 2: 1.
108. Hu S, Niu H, Minkin P, et al. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Mol Cancer Ther 2008; 7: 1110-20.
109. Kirken RA, Erwin RA, Taub D, et al. Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J Leukoc Biol 1999; 65: 891-9.
110. Chase A, Grand FH, Cross NC. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 2007; 110: 3729-34.